Why the Acrux Limited share price was hammered in July

Acrux Limited (ASX:ACR) shares fell 20% during July, although they've staged a minor recovery since.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shareholders of Acrux Limited (ASX: ACR) were rendered helpless in July as their shares plunged 20%, falling from 85 cents to just 68 cents.

Acrux is a junior pharmaceutical business which a market capitalisation around $120 million. The company uses innovative technology to administer medicines through the skin, including its flagship Axiron product which is used to treat adult males who have low or no testosterone.

Unfortunately for investors, Axiron sales were well down for the three months ended June 30 2015 at just US$32.4 million, compared to the US$39.1 million reported in the prior quarter. Sales for the period were also more than 31% lower than the prior corresponding period (the three months ended 30 June 2014).

Indeed, this can partially be attributed to stricter requirements issued by the US Food and Drug Administration (FDA) surrounding testosterone therapy products such as Axiron.

As fate would have it, labelling on the drug now needs to inform users of the potentially increased risk of heart attack and stroke while doctors have also been ordered to only prescribe the treatment to men who suffer low testosterone caused by certain medical conditions. That is, doctors can no longer prescribe the treatment due to ageing or various other reasons unless the reasons are FDA-approved.

Acrux's shares fell to a 52-week low of just 62.5 cents early last week but have since recovered to trade at 73 cents – up 7.4% since the beginning of the month. While there is no telling whether or not the shares can continue to climb in the near-term, Acrux looks like a company Foolish investors should avoid for now.

Motley Fool contributor Ryan Newman has no position in any stocks mentioned. You can follow Ryan on Twitter @ASXvalueinvest. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »